DE60037394T2 - VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE - Google Patents

VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE Download PDF

Info

Publication number
DE60037394T2
DE60037394T2 DE60037394T DE60037394T DE60037394T2 DE 60037394 T2 DE60037394 T2 DE 60037394T2 DE 60037394 T DE60037394 T DE 60037394T DE 60037394 T DE60037394 T DE 60037394T DE 60037394 T2 DE60037394 T2 DE 60037394T2
Authority
DE
Germany
Prior art keywords
alkyl
use according
inhibitor
cancer
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60037394T
Other languages
German (de)
English (en)
Other versions
DE60037394D1 (de
Inventor
Andrei V. Glencoe GUDKOV
Pavel G. Oak Park KOMAROV
Elena A. Oak Park KOMAROVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois
University of Illinois at Urbana Champaign
Original Assignee
University of Illinois
University of Illinois at Urbana Champaign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22375329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60037394(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Illinois, University of Illinois at Urbana Champaign filed Critical University of Illinois
Publication of DE60037394D1 publication Critical patent/DE60037394D1/de
Application granted granted Critical
Publication of DE60037394T2 publication Critical patent/DE60037394T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60037394T 1999-01-29 2000-01-28 VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE Expired - Lifetime DE60037394T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11788199P 1999-01-29 1999-01-29
US117881P 1999-01-29
PCT/US2000/002104 WO2000044364A2 (fr) 1999-01-29 2000-01-28 INHIBITEURS DE p53 ET UTILISATION THERAPEUTIQUE DE CEUX-CI

Publications (2)

Publication Number Publication Date
DE60037394D1 DE60037394D1 (de) 2008-01-24
DE60037394T2 true DE60037394T2 (de) 2009-01-02

Family

ID=22375329

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60037394T Expired - Lifetime DE60037394T2 (de) 1999-01-29 2000-01-28 VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE

Country Status (11)

Country Link
US (7) US6593353B1 (fr)
EP (1) EP1143943B1 (fr)
JP (2) JP2002535357A (fr)
AT (1) ATE380548T1 (fr)
AU (1) AU3584200A (fr)
CA (1) CA2360671A1 (fr)
DE (1) DE60037394T2 (fr)
IL (3) IL144294A0 (fr)
NZ (1) NZ513487A (fr)
WO (1) WO2000044364A2 (fr)
ZA (1) ZA200105823B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60037394T2 (de) * 1999-01-29 2009-01-02 The Board Of Trustees For The University Of Illinois, Urbana VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
AU7887501A (en) * 2000-07-06 2002-01-21 Us Gov Health & Human Serv Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
AU2001294515A1 (en) * 2000-08-11 2002-02-25 The Regents Of The University Of California Use of stat-6 inhibitors as therapeutic agents
WO2002076439A2 (fr) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Composes capables de moduler l'activite de transporteurs de medicaments multiples et leur utilisation therapeutique
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
WO2004089345A1 (fr) * 2003-04-03 2004-10-21 Semafore Pharmaceuticals Inc. Ciblage osseux de nanoparticules biodegradables contenant un medicament
WO2004089356A2 (fr) * 2003-04-03 2004-10-21 Semafore Pharmaceuticals Inc. Agents de protection cibles de la moelle osseuse
US7657893B2 (en) * 2003-04-23 2010-02-02 International Business Machines Corporation Accounting method and logic for determining per-thread processor resource utilization in a simultaneous multi-threaded (SMT) processor
US7132421B2 (en) * 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
WO2005019440A1 (fr) * 2003-08-20 2005-03-03 Northern Sydney And Central Coast Area Health Service Methodes pouvant ameliorer la viabilite d'un embryon
WO2006021954A2 (fr) 2004-08-23 2006-03-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Inhibiteurs peptidiques permettant de traiter des reponses au stress
CA2580126C (fr) * 2004-09-28 2014-08-26 Quark Biotech, Inc. Oligoribonucleotides et procedes d'utilisation associes pour le traitement de l'alopecie, des insuffisances renales aigues et d'autres maladies
CA2587406A1 (fr) * 2004-11-16 2006-05-26 Limerick Neurosciences, Inc. Procedes et compositions de traitement de douleurs
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
US9066976B2 (en) 2005-11-11 2015-06-30 Korea Research Institute Of Bioscience And Biotechnology Method for therapeutic angiogenesis
KR100877824B1 (ko) * 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
US20070110756A1 (en) * 2005-11-14 2007-05-17 Reinberg Danny F Method for modulating P53 activity via methylation
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
CN101605798A (zh) * 2006-12-14 2009-12-16 第一三共株式会社 咪唑并噻唑衍生物
FR2910895B1 (fr) * 2006-12-29 2010-08-27 Biopharmed "derives d'imino-tetrahydrobenzotriazoles ayant des proprietes anti-migratoires de metastases met dependantes"
CA2677045C (fr) * 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilises et utilisations de ceux-ci
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
ES2474176T3 (es) * 2007-06-27 2014-07-08 Quark Pharmaceuticals, Inc. Composiciones y métodos para inhibir la expresión de genes pro-apopt�ticos
JP5340265B2 (ja) * 2008-06-27 2013-11-13 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
US20110224221A1 (en) * 2008-10-01 2011-09-15 Sharpless Norman E Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
AU2009298367A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
WO2010080452A2 (fr) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. Composés d'arnsi et leurs procédés d'utilisation
US20120100100A1 (en) 2009-05-13 2012-04-26 Sharpless Norman E Cyclin dependent kinase inhibitors and methods of use
WO2011016588A1 (fr) 2009-08-07 2011-02-10 Kyoto University Procédé permettant d'établir de façon efficace des cellules souches pluripotentes induites
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2012037283A2 (fr) * 2010-09-14 2012-03-22 Mount Sinai School Of Medicine Administration d'agents neuroprotecteurs du sns pour favoriser la régénération hématopoïétique
CA2818046A1 (fr) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection des tissus renaux contre l'ischemie par le biais de l'inhibition des kinases proliferatives cdk4 et cdk6
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US9987302B2 (en) 2011-08-09 2018-06-05 Beth Israel Deaconess Medical Center, Inc. Methods of treating DNA damage
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
AU2013315524B2 (en) 2012-09-12 2019-01-31 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
EP2968291A4 (fr) 2013-03-15 2016-09-28 G1 Therapeutics Inc Traitements épargnant hspc pour la prolifération cellulaire anormale rb positive
US10314826B2 (en) 2014-02-07 2019-06-11 University Of Maryland, Baltimore Methods of treatment of ischemia-induced angiogenesis and arteriogenesis
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
KR20170007492A (ko) 2014-05-29 2017-01-18 쿠아크 파마수티칼스 인코퍼레이티드 장기에서의 허혈 재관류 손상 방지 방법 및 방지용 조성물
EP3191098A4 (fr) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinaisons et régimes posologiques pour traiter des tumeurs rb-positives
WO2016040848A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Traitement de tumeurs rb-négatives en utilisant des inhibiteurs de la topoisomérase en association avec des inhibiteurs des kinases cycline-dépendantes 4/6
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (fr) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
EP3405194A1 (fr) 2016-01-18 2018-11-28 Institut National de la Sante et de la Recherche Medicale (INSERM) Utilisation d'un inhibiteur temporaire de p53 à des fins de prévention ou de réduction des rechutes de cancer
WO2018083606A1 (fr) 2016-11-01 2018-05-11 Novartis Ag Procédés et compositions pour améliorer l'édition de gènes
WO2020023502A1 (fr) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et utilisations associées
US20220175848A1 (en) 2019-04-01 2022-06-09 The Broad Institute, Inc. Methods and compositions for cell therapy
WO2020247336A1 (fr) * 2019-06-03 2020-12-10 The Regents Of The University Of California Analogues de pifithrine et méthodes de traitement du syndrome de rett
JP7429035B2 (ja) * 2019-08-01 2024-02-07 東京都公立大学法人 機能不全ミトコンドリアを消去するための複合体、および細胞老化を抑制するための複合体
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2024052434A1 (fr) 2022-09-06 2024-03-14 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modification par génie génétique de l'hétérodimérisation sox/oct afin d'induire une réinitialisation du développement de haut niveau

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
CA2028756A1 (fr) * 1989-11-24 1991-05-25 Alfons H. M. Raeymaekers Immunostimulation de derives de 6-aryl-5,6-dihydro-imidazo[2,1-b]thiazole
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
CA2215197A1 (fr) 1995-03-13 1996-09-19 Shigeyuki Tasaka Compose imidazothiazole
JP3847366B2 (ja) * 1996-02-22 2006-11-22 アンジェスＭｇ株式会社 アンチセンスオリゴヌクレオチドを用いた固定性分裂終了細胞増殖剤
US5919808A (en) 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
EP0973513A4 (fr) 1996-10-23 2003-03-19 Zymogenetics Inc Compositions et methodes pour traiter les etats associes a un deficit osseux
JPH1129475A (ja) 1997-07-07 1999-02-02 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
JPH11103640A (ja) 1997-09-29 1999-04-20 Mitsubishi Agricult Mach Co Ltd ノッタの結節装置
JPH11106340A (ja) 1997-10-02 1999-04-20 Sumitomo Pharmaceut Co Ltd Ｓｔａｔ６活性化阻害剤
DE60037394T2 (de) * 1999-01-29 2009-01-02 The Board Of Trustees For The University Of Illinois, Urbana VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE

Also Published As

Publication number Publication date
US20020019425A1 (en) 2002-02-14
US20020006941A1 (en) 2002-01-17
JP2010265321A (ja) 2010-11-25
DE60037394D1 (de) 2008-01-24
US20030144331A1 (en) 2003-07-31
EP1143943B1 (fr) 2007-12-12
WO2000044364A3 (fr) 2001-08-23
US20030176318A1 (en) 2003-09-18
WO2000044364A2 (fr) 2000-08-03
AU3584200A (en) 2000-08-18
EP1143943A3 (fr) 2002-09-11
US20050222224A1 (en) 2005-10-06
US7008956B2 (en) 2006-03-07
IL144294A (en) 2010-04-15
NZ513487A (en) 2003-02-28
US7012087B2 (en) 2006-03-14
JP2002535357A (ja) 2002-10-22
CA2360671A1 (fr) 2000-08-03
ATE380548T1 (de) 2007-12-15
US20080161426A1 (en) 2008-07-03
US6982277B2 (en) 2006-01-03
ZA200105823B (en) 2002-05-07
EP1143943A2 (fr) 2001-10-17
US6593353B1 (en) 2003-07-15
IL195723A (en) 2010-12-30
IL144294A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
DE60037394T2 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE69202441T2 (de) Melatoninderivate und Kombinationen mit Antiestrogenen zur Behandlung von Brustkarzinoma.
DE69729798T2 (de) Therapeutische behandlung von vegf-bedingten augenkrankheiten
DE102005056890A1 (de) Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut
DE3611194A1 (de) Cancerostatisches mittel
DE69632854T2 (de) Schutzmittel für Organe und Gewebe
DE69710111T2 (de) Behandlung und Prophylaxe von Pankreatitis
DE69614407T2 (de) Pharmazeutische zusammensetzungen
DE69009717T2 (de) Heteroaryl-3-oxo-propan-nitril-derivat verwendbar in erregung von myelopoiesis.
DE60316297T2 (de) Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind
CH644864A5 (de) Psoralenderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate.
DE3419935A1 (de) Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks
DE60216142T2 (de) Tropan-Derivate mit einer die Wiederaufnahme von Dopamin hemmenden Aktivität zur Behandlung von ischämischen Erkrankungen
DE2349538A1 (de) Arzneimittel zur behandlung von lebererkrankungen
DE3779991T2 (de) Dioxopiperidin-derivate enthaltende anxiolytische zusammensetzungen.
DE4202184A1 (de) Substituierte salicylaldehyde zur behandlung von krankheiten
DE60011060T2 (de) Virus behandlung
DE69819192T2 (de) Neue cyanoaziridine zur behandlung von krebs
DE60110628T2 (de) Antiphlogistische mittel
EP1797880A2 (fr) Utilisation d'inhibiteurs P53 pour traiter les effets secondaires d'un traitement contre le cancer
DE60210329T2 (de) Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren
EP1087768B1 (fr) Utilisation de derives de 1-(aminoalkyl)-3-quinoxalin-2-one pour produire des compositions a action antioxydante
DE4217396A1 (de) Metrifonat enthaltendes Arzneimittel
EP2130832A1 (fr) Complexes organiques de cuivre, leur utilisation en tant que produit anti-tumeur et pour la protection des tissus sains contre le rayonnement ionisant
JP4553354B2 (ja) 抗トリパノソーマ剤

Legal Events

Date Code Title Description
8363 Opposition against the patent